IGFBP-2 acts as a tumour suppressor and plays a role in determining chemosensitivity in bladder cancer cells

There are mixed reports on the role that IGFBP-2 plays in cancer progression, with some indicating a tumour suppressive role and others showing that IGFBP-2 may act as an oncogene. These apparent contradictions may be context and tissue specific. In this study we determined the role that IGFBP-2 played on the phenotype and chemosensitivity of a selection of bladder cancer cell lines and investigated how the abundance of IGFBP-2 was regulated. We found that IGFBP-2 was more abundant in the epithelial bladder cancer cells, RT4 and UMUC3 and absent in the more mesenchymal T24 and TCCSUP cells. Silencing IGFBP-2 using siRNA in epithelial RT4 cells promoted cell proliferation, invasion, colony formation, resulted in a reduction in epithelial (E-cadherin) and an increase in mesenchymal (N-cadherin) markers and increased sensitivity to cisplatin-induced cell death. Conversely, we observed the opposite effects when adding exogenous IGFBP-2 to the mesenchymal T24 cells. We determined that IGFBP-2 was epigenetically silenced via DNA methylation as the cells adopted a mesenchymal phenotype. Collectively these data suggest that IGFBP-2 acts as a tumour suppressor and marker of chemosensitivity in epithelial bladder cancer cells and that IGFBP-2 is epigenetically silenced by methylation to promote bladder cancer progression.

[1]  D. McConkey,et al.  ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers. , 2019, European urology.

[2]  J. Holly,et al.  Inhibition of FASN and ERα signalling during hyperglycaemia-induced matrix-specific EMT promotes breast cancer cell invasion via a caveolin-1-dependent mechanism , 2018, Cancer letters.

[3]  P. Wei,et al.  IGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasis , 2017, Oncotarget.

[4]  Wei Zhang,et al.  IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma. , 2016, Cancer research.

[5]  J. Vadgama,et al.  Epithelial-Mesenchymal Transition and Breast Cancer , 2016, Journal of clinical medicine.

[6]  Dong Wang,et al.  Inhibition of IGFBP-2 improves the sensitivity of bladder cancer cells to cisplatin via upregulating the expression of maspin. , 2015, International journal of molecular medicine.

[7]  C. Wheeler,et al.  HPV16 Down-Regulates the Insulin-Like Growth Factor Binding Protein 2 to Promote Epithelial Invasion in Organotypic Cultures , 2015, PLoS pathogens.

[8]  A. Wu,et al.  Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway , 2014, British Journal of Cancer.

[9]  M. Knowles,et al.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity , 2014, Nature Reviews Cancer.

[10]  C. Zhang,et al.  IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells , 2013, Journal of Hematology & Oncology.

[11]  D. Gillatt,et al.  Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. , 2013, Endocrine-related cancer.

[12]  L. Zeng,et al.  Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells. , 2013, Experimental cell research.

[13]  L. Zeng,et al.  Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. , 2013, Endocrinology.

[14]  C. Lim,et al.  Tumor dissemination: an EMT affair. , 2013, Cancer cell.

[15]  J. Holly,et al.  Insulin-like growth factor physiology: what we have learned from human studies. , 2012, Endocrinology and metabolism clinics of North America.

[16]  Kamaleshwar P Singh,et al.  DNA demethylation by 5-aza-2-deoxycytidine treatment abrogates 17 beta-estradiol-induced cell growth and restores expression of DNA repair genes in human breast cancer cells. , 2012, Cancer letters.

[17]  D. Gillatt,et al.  Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel , 2011, British Journal of Cancer.

[18]  A. Moon,et al.  Epithelial-mesenchymal Transition and Cell Invasion , 2010, Toxicological research.

[19]  L. Zeng,et al.  Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. , 2010, Endocrine-related cancer.

[20]  M. Pollak,et al.  IGFBP‐2 Expression in MCF‐7 Cells is Regulated by the PI3K/AKT/mTOR Pathway through Sp1 Induced Increase in Transcription , 2010, Growth factors.

[21]  T. Seyfried,et al.  A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion , 2010, Journal of Neuro-Oncology.

[22]  C. Dinney,et al.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer , 2009, Cancer and Metastasis Reviews.

[23]  G. Fuller,et al.  IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas , 2009, Proceedings of the National Academy of Sciences.

[24]  Ignacio Ramis-Conde,et al.  Multi-scale modelling of cancer cell intravasation: the role of cadherins in metastasis , 2009, Physical biology.

[25]  R. Sikes,et al.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. , 2009, American journal of translational research.

[26]  Hiroaki Kataoka,et al.  Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma. , 2007, Anticancer research.

[27]  C. Perks,et al.  IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells , 2007, Oncogene.

[28]  A. Hoeflich,et al.  IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. , 2006, Journal of molecular endocrinology.

[29]  Tetsuhiro Chiba,et al.  Identification and investigation of methylated genes in hepatoma. , 2005, European journal of cancer.

[30]  M. Gleave,et al.  Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. , 2005, Oncology reports.

[31]  Tanja Woyke,et al.  Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. , 2005, Neoplasia.

[32]  N. Ling,et al.  Identification of a Nonpeptide Ligand That Releases Bioactive Insulin-like Growth Factor-I from Its Binding Protein Complex* , 2001, The Journal of Biological Chemistry.

[33]  E. Wolf,et al.  Insulin‐like growth factor‐binding protein‐2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF‐responsive colon carcinoma cell lines , 1998, FEBS letters.